MECOM and myeloid neoplasm: How commonly the co-occurring genetic alterations and mutations, e.g., monosomy 7 and RAS pathway mutations, and their order of acquisition, contribute to the aggressive phenotype and therapy-refractoriness of EVI1-overexpressing myeloid malignancies has yet to be fully characterized.